Insmed raises full-year revenue guidance for Brinsupri to between $1.25 billion and $1.40 billion following stronger Q2 results.
Insmed shares surged approximately 33% in early trading after the company increased its full-year revenue forecast for Brinsupri, a treatment for chronic lung disease, to a range of $1.25 billion to $1.40 billion. The previous guidance targeted at least $1 billion in sales.
The revised outlook follows better-than-expected Q2 financial performance, with results surpassing expectations on both revenue and earnings. Brinsupri has shown strong demand, driving the upward adjustment in projections.
The stock rally reflects investor confidence in the drug’s commercial potential and Insmed’s growth trajectory.